Cantor Fitzgerald Maintains a 'Buy' on Forest Laboratories (FRX); Raising PT and Estimates
Tweet Send to a FriendGet Alerts FRX Hot Sheet
Price: $38.53 -0.44%
Rating Summary:
9 Buy, 9 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
9 Buy, 9 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade FRX Now!
Cantor Fitzgerald maintains a 'Buy' on Forest Laboratories (NYSE: FRX) price target raised from $41 to $45.
Analyst, Irina Rivkind, said, "Management guided to revenues of $3.4B and adjusted EPS of $1.20-1.35. We cannot get to a similar top line (which incorporates aggressive growth of Namenda, Bystolic, and the new launches) and assume lower revenues of $3.2B. We are adhering to the company's guidance for operational expenses, which we believe is more realistic, and taken together, this results in a $0.60 EPS estimate for the year. We think that investors are big-picture-focused and that the outlook has shifted beyond Lexapro. We continue to believe that the stock is fundamentally undervalued and upcoming PDUFAs for Linaclotide (early June) and Aclidinium (late July), as well as the Investor Day on June 20, should continue to drive share appreciation."
Raises FY12 EPS estimate from $3.69 to $3.77 and FY13 from $0.50 to $0.60.
For an analyst ratings summary and ratings history on Forest Laboratories click here. For more ratings news on Forest Laboratories click here.
Shares of Forest Laboratories closed at $34.97 yesterday, with a 52 week range of $28.47-$40.52.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Irina Rivkind, said, "Management guided to revenues of $3.4B and adjusted EPS of $1.20-1.35. We cannot get to a similar top line (which incorporates aggressive growth of Namenda, Bystolic, and the new launches) and assume lower revenues of $3.2B. We are adhering to the company's guidance for operational expenses, which we believe is more realistic, and taken together, this results in a $0.60 EPS estimate for the year. We think that investors are big-picture-focused and that the outlook has shifted beyond Lexapro. We continue to believe that the stock is fundamentally undervalued and upcoming PDUFAs for Linaclotide (early June) and Aclidinium (late July), as well as the Investor Day on June 20, should continue to drive share appreciation."
Raises FY12 EPS estimate from $3.69 to $3.77 and FY13 from $0.50 to $0.60.
For an analyst ratings summary and ratings history on Forest Laboratories click here. For more ratings news on Forest Laboratories click here.
Shares of Forest Laboratories closed at $34.97 yesterday, with a 52 week range of $28.47-$40.52.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Wells Fargo Downgrades Aruba Networks (ARUN) to Market Perform
- UPDATE: Vanda Pharmaceuticals (VNDA) Opens Higher; Lazard Raises PT to $17
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Cantor Fitzgerald
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
